Publications by authors named "Beate Rottenmanner"
Neuro Oncol
December 2024
Article Synopsis
- Brain metastases (BM) are a critical issue for patients with HER2-positive metastatic breast cancer, necessitating better treatment options; the study examined the effectiveness of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) compared to trastuzumab emtansine.*
-
- In the TUXEDO-1 trial involving patients with HER2-positive BC and active BM, the results showed a median progression-free survival (PFS) of 21 months and an overall survival (OS) that had not been reached at 26.5 months of follow-up, indicating positive outcomes for T-DXd.*
-
- No new safety concerns emerged throughout the trial, with fatigue being the most reported
Article Synopsis
- - The TUXEDO-1 trial tested trastuzumab deruxtecan, an antibody-drug conjugate, on 15 patients with HER2-positive metastatic breast cancer and brain metastases, focusing on its ability to treat brain lesions.
- - Results showed a significant intracranial response rate, with 73.3% of patients achieving a complete or partial response, which exceeded the trial's target of 61%.
- - Safety was consistent with previous findings, and patients maintained their quality of life and cognitive function during treatment, suggesting trastuzumab deruxtecan could be a viable option for managing brain metastases in these patients.
